In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chemistry Firms Still Second Fiddle in Biology-Chemistry Mergers

Executive Summary

With a scarcity of well-trained chemists and exponentially increasing numbers of genomics-generated targets contributing to an already bulging lead identification/optimization bottleneck, medicinal chemistry capabilities are at a premium. Nonetheless, when it comes to market valuations, biology companies still come out on top. And Celera's recent acquisition of Axys, along with Lexicon Genetics purchase of Coelacanth help prove the point.

You may also be interested in...



Inside Applera: Celera Genomics Becomes Applied Bio's Diagnostics Angel

Applera Corp.'s new $75 million high-throughput genotyping initiative to be equally funded by its three businesses, Celera Genomics Group, Applied Biosystems Group, and Celera Diagnostics (a joint venture of Celera Genomics and Applied Bio) has provided a context for the company to begin to reveal its diagnostics strategy. New information about the structure of the joint venture also sheds more light on the acceleration of Celera Genomics' business strategy as it moves toward a collaborator-oriented drug discovery company model.

Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel